Impact of neuroleptic chemotherapies on schizophrenic psychoses
Abstract
The author reviews the impact of neuroleptic chemotherapy on various forms of schizophrenia in the 25 years since the introduction of chlorpromazine in psychiatry. The activities of the different types of compounds are related to the symptomatic and progressive forms of the psychosis, with an emphasis on the "dual structure" of the illness. Problems of drug efficacy, the need for new drug treatments, and methodological issues in research in these areas are discussed.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
